Currie G, Delles C
Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Curr Diab Rep. 2016 Nov;16(11):104. doi: 10.1007/s11892-016-0798-3.
The last decade has seen a surge in publications describing novel biomarkers for early detection of diabetic nephropathy (DN), but as yet none have outperformed albuminuria in well-designed prospective studies. This is partially attributable to our incomplete understanding of the many complex interrelated mechanisms underlying DN development, a heterogeneous process unlikely to be captured by a single biomarker. Proteomics offers the advantage of simultaneously analysing the entire protein content of a biological sample, and the technique has gained attention as a potential tool for a more accurate diagnosis of disease at an earlier stage as well as a means by which to unravel the pathogenesis of complex diseases such as DN using an untargeted approach. This review will discuss the potential of proteomics as both a clinical and research tool, evaluating exploratory work in animal models as well as diagnostic potential in human subjects.
在过去十年中，描述用于早期检测糖尿病肾病（DN）的新型生物标志物的出版物激增，但在精心设计的前瞻性研究中，尚无一种生物标志物的表现优于蛋白尿。这部分归因于我们对DN发生背后许多复杂相互关联机制的理解不完整，DN是一个异质性过程，不太可能由单一生物标志物来体现。蛋白质组学具有同时分析生物样品中全部蛋白质含量的优势，该技术作为一种在更早阶段更准确诊断疾病的潜在工具，以及一种使用非靶向方法揭示诸如DN等复杂疾病发病机制的手段，已受到关注。本综述将讨论蛋白质组学作为临床和研究工具的潜力，评估在动物模型中的探索性工作以及在人类受试者中的诊断潜力。
